Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus [0.03%]
塞浦路斯能承担Luspatercept的成本吗？一项关于将Luspatercept纳入医保以治疗塞浦路斯地区输血依赖型地中海贫血患者所带来的预算影响分析
Olga Pitsillidou,Panagiotis Petrou,M J Postma
Olga Pitsillidou
Objective: This study aims to estimate the budget impact of luspatercept reimbursement as an adjuvant to the standard management of β-thalassaemia major in Cyprus, from a societal perspective, and assess the financial fe...
Shahzad Ghanbarian,Gavin W K Wong,Mary Bunka et al.
Shahzad Ghanbarian et al.
Background: Major depressive disorder (MDD) is a common, often recurrent condition and a significant driver of healthcare costs. People with MDD often receive pharmacological therapy as the first-line treatment, but the m...
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany [0.03%]
德国中重度B型血友病患者使用Etranacogene dezaparvovec与长效预防治疗的 cost-effectiveness 分析
Niklaus Meier,Hendrik Fuchs,Katya Galactionova et al.
Niklaus Meier et al.
Background and objective: Haemophilia B is a rare genetic disease that is caused by a deficiency of coagulation factor IX (FIX) in the blood and leads to internal and external bleeding. Under the current standard of care,...
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab [0.03%]
接受曲妥珠单抗治疗的人类表皮生长因子受体2阳性转移性乳腺癌女性的相关生活质量的系统回顾
Sudewi Mukaromah Khoirunnisa,Fithria Dyah Ayu Suryanegara,Lisa Aniek de Jong et al.
Sudewi Mukaromah Khoirunnisa et al.
Background: Many trials of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treatment with trastuzumab have provided evidence of improved clinical outcomes. This systematic review examined...
Identification and prioritisation of items for a draft participant-reported questionnaire to measure use of social care, informal care, aids and adaptations [0.03%]
识别和优先排序项目以制定问卷草稿来测量社会照护、非正式照护、辅助器具及适应性改造的使用情况
Kirsty M Garfield,Gail A Thornton,Samantha Husbands et al.
Kirsty M Garfield et al.
Background: Resource-use measurement is integral for assessing cost-effectiveness within trial-based economic evaluations. Methods for gathering resource-use data from participants are not well developed, with questionnai...
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales [0.03%]
大不列颠和威尔士结节性硬化症复合物相关性癫痫使用添加cbd治疗与常规治疗的成本效用分析
Colin Burke,Catriona Crossan,Emma Tyas et al.
Colin Burke et al.
Objectives: The aim of this study was to evaluate the cost effectiveness of plant-derived highly purified cannabidiol (Epidyolex® in the UK; 100 mg/mL oral solution) as an add-on treatment to usual care for the managemen...
Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis [0.03%]
法瑞西单抗治疗糖尿病黄斑水肿(DMO)的成本效益分析：英国研究报告
Christian Bührer,Thomas Paling,Richard Gale et al.
Christian Bührer et al.
Aim: The aim of this work was to evaluate the cost-effectiveness of faricimab against relevant therapeutic alternatives used in clinical practice for the treatment of diabetic macular oedema (DMO) in the UK. ...
Cost-Effectiveness of Routine Monitoring of Long-Term Conditions in Primary Care: Informing Decision Modelling with a Systematic Review in Hypertension, Type 2 Diabetes and Chronic Kidney Disease [0.03%]
初级保健中对长期性疾病进行常规监测的成本效益分析：以系统回顾高血压、二型糖尿病和慢性肾病为依据构建决策模型
Syed G Mohiuddin,Mary E Ward,William Hollingworth et al.
Syed G Mohiuddin et al.
Background: Long-term conditions (LTCs) are major public health problems with a considerable health-related and economic burden. Modelling is key in assessing costs and benefits of different disease management strategies,...
Correction: From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy [0.03%]
修正：从基于药品疗效定价到混合方法：意大利药品价格和报销谈判的案例证据
Elvio Emanuele Rossini,Carlotta Galeone,Chiara Lucchetti et al.
Elvio Emanuele Rossini et al.
Published Erratum
PharmacoEconomics - open. 2024 Mar;8(2):345. DOI:10.1007/s41669-024-00475-w 2024
Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models [0.03%]
人工智能在网状 meta 分析中的自动化应用：四个案例研究评估大型语言模型的潜在应用
Tim Reason,Emma Benbow,Julia Langham et al.
Tim Reason et al.
Background: The emergence of artificial intelligence, capable of human-level performance on some tasks, presents an opportunity to revolutionise development of systematic reviews and network meta-analyses (NMAs). In this ...